Peer-influenced content. Sources you trust. No registration required. This is HCN.
UCSF MedConnection
Explore the potential of IS-002, an imaging agent that offers a new dimension in intraoperative prostate cancer detection, promising a more targeted approach to surgical intervention and patient management.
Oncology, Medical March 4th 2024
Clinical Advances in Hematology & Oncology
Understanding the complexities of neuroendocrine prostate cancer (NEPC) is crucial for advancing diagnosis and treatment. Insights into lineage plasticity and novel diagnostic tools, including PET imaging and liquid biopsies, are paving the way for more effective management strategies.
Oncology, Medical February 20th 2024
Cancer Therapy Advisor
Recent studies highlight the potential of cabozantinib plus atezolizumab in improving progression-free survival for mCRPC patients and confirm the benefits of high-dose radiotherapy in high-risk prostate cancer treatment, offering new insights into personalized care strategies.
Mayo Clinic
In a significant advancement, one physician’s minimally invasive technique for treating membranous urethral strictures post-radiation therapy showcases promising outcomes, including improved urethral patency and reduced operative complications, marking a pivotal shift in patient management strategies.
Urology February 5th 2024
OBR Oncology
In the phase 3 GETUG-AFU 18 trial, high-dose radiotherapy (80 Gy) combined with long-term androgen deprivation therapy markedly improved 10-year progression-free and overall survival in high-risk prostate cancer patients, without additional toxicity.
Oncology, Medical February 5th 2024
Renal & Urology News
In a landmark study, researchers found that each doubling of PSA levels in men over 70 doubles the risk of prostate cancer death, highlighting the critical need for tailored screening approaches in older patients.
Geriatrics January 16th 2024